| 2.17 0.08 (3.83%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.76 |
1-year : | 3.23 |
| Resists | First : | 2.36 |
Second : | 2.76 |
| Pivot price | 1.88 |
|||
| Supports | First : | 1.89 |
Second : | 1.6 |
| MAs | MA(5) : | 2.02 |
MA(20) : | 1.92 |
| MA(100) : | 2.3  |
MA(250) : | 2.42 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 72.6 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 4.67 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MBOT ] has closed below upper band by 0.5%. Bollinger Bands are 10.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.37 - 2.38 | 2.38 - 2.39 |
| Low: | 2.05 - 2.06 | 2.06 - 2.07 |
| Close: | 2.15 - 2.17 | 2.17 - 2.18 |
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Thu, 12 Feb 2026
Microbot Medical Inc Highlights LIBERTY System at ISET Conference - TradingView
Thu, 12 Feb 2026
Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference - Yahoo Finance
Thu, 12 Feb 2026
The only FDA-cleared single-use vascular robot just took center stage in Miami - Stock Titan
Wed, 11 Feb 2026
Looking Into Microbot Medical Inc's Recent Short Interest - Benzinga
Tue, 10 Feb 2026
Microbot Medical Advances with LIBERTY Clearance Driving Market Expansion - StocksToTrade
Tue, 10 Feb 2026
This Microbot Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Tuesday - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 67 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 15.6 (%) |
| Shares Short | 6,830 (K) |
| Shares Short P.Month | 6,420 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.2 % |
| Return on Equity (ttm) | -31.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -4.83 |
| PEG Ratio | 0 |
| Price to Book value | 1.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|